Nufarm (ASX:NUF) Extends bp Carinata Deal to 2050: Is This a Turning Point for a Stock Down More Than 50%?

Nufarm Extends Key bp Biofuels Deal

Nufarm (ASX: NUF) has had a rough run. The stock has lost more than half its value over the past 12 months, and frustrated investors have been asking the same question for months: Is there a genuine recovery story here, or is this a value trap? Recent news doesn’t answer that question completely, but it does move the needle. Nufarm has extended its biofuels partnership with bp all the way to 2050, locking in long-term demand for its Carinata crop and introducing a co-funding model that means growth won’t require Nufarm to reach into its own pockets. For a company carrying real balance sheet pressure, that distinction matters more than it might first appear.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Why the bp Deal Is More Important Than It Looks

Carinata is a non-food oilseed crop that farmers grow between their main crop seasons. It doesn’t compete with food production; it improves soil health, and crucially, the oil it produces can be refined into sustainable aviation fuel, one of the most in-demand commodities in clean energy right now. Airlines and heavy transport operators are under serious regulatory pressure to cut emissions by 2030, and the supply of sustainable fuel feedstocks is nowhere near enough to meet that demand. Nufarm’s Carinata sits right in the middle of that gap.

The fact that bp has committed to this partnership until 2050 signals something important: this isn’t a trial. It’s a long-term commercial relationship with one of the world’s biggest energy companies. That kind of anchor gives Nufarm the credibility to expand its grower network, scale production across more countries, and attract the kind of institutional attention the Carinata platform has so far struggled to generate.

What’s equally significant is the capital-light structure. Nufarm won’t need to fund this growth itself, as bp co-funds the expansion. For investors worried about Nufarm’s debt levels, this is genuinely good news. The Carinata platform can scale without making the balance sheet problem worse.

The Honest Assessment

Here’s where we have to be straight with investors. The bp deal is a long-term positive, but Nufarm still has real problems to work through right now. The company reported a statutory loss of A$165 million in FY25, largely tied to write-downs in its Omega-3 business, a division that has consistently disappointed and forced management to scale back production. That overhang hasn’t disappeared.

The bright spot in FY25 was Crop Protection, which delivered 18% earnings growth across all regions. That’s the core of the business, and it’s genuinely performing well. If that momentum continues into FY26, and management delivers on its promise to bring debt levels down meaningfully by year-end, the recovery thesis starts to look credible. But execution risk is real, and there’s limited margin for error.

The Investors’ Takeaway

We believe the recent announcement improves the long-term investment case for Nufarm in a way that shouldn’t be dismissed. It removes a key uncertainty around whether Carinata had a serious future, and the answer is now clearly yes.

That said, this isn’t a stock for investors chasing short-term gains. NUF is a recovery play that needs time and execution. Analyst consensus points to meaningful upside from current levels, but the wide range of price targets reflects how divided the market is.

In our view, patient investors with a 2-3 year view and an appetite for some risk will find the current entry point increasingly interesting. Those who want cleaner confirmation may prefer to wait for the May half-year result, which will tell us whether the FY26 recovery is real or still a work in progress.